Immunophotonics will participate in LSI USA ’26, held March 16–20, 2026, at the Waldorf Astoria Monarch Beach in Dana Point, California. During the conference, Miguel Zubizarreta, CEO, will share company updates and highlight progress in advancing Interventional Immuno‑Oncology®.

The presentation is focused on Immunophotonics’ efforts to address cancer recurrence, one of the most significant challenges in oncology. The company’s lead candidate, IP‑001, is designed to activate systemic anti‑tumor immunity following routine local tumor ablation, with the goal of enabling durable immune response.

LSI USA ’26 provides an opportunity to engage with investors, strategic partners, and industry leaders as Immunophotonics continues to advance its clinical development programs.